Vertex CF Treatments Opening to Eligible Patients in France and Italy 

Vertex CF Treatments Opening to Eligible Patients in France and Italy 

298057

Vertex CF Treatments Opening to Eligible Patients in France and Italy 

Vertex Pharmaceuticals has reached reimbursement agreements with health authorities in France and Italy for its various cystic fibrosis (CF) treatments, including Kaftrio (ivacaftor/tezacaftor/elexacaftor), a next-generation therapy approved for use with ivacaftor. With these agreements — which bring the treatments into each country’s public health program — about 3,000 CF patients in France and Italy will gain access for the first time to more or all of Vertex’s CFTR modulators. Kaftrio — marketed as Trikafta in the U.S.…

You must be logged in to read/download the full post.